Due to a production error, there was a mistake in Table 2 as published. The four “>“ in the column of “p-value” in Table 2 should all be “<“. The corrected Table 2 appears below. The publisher apologizes for this mistake.
Table 2
| Cytokine levels (pg/ml) | APS group (n=37) | Heathy control group (n=31) a | P-value |
|---|---|---|---|
| IL-2 | 2.54 (1.80-3.47) | 1.86 (1.44-2.38) | 0.008** |
| IL-4 | 2.87 (1.82-4.58) | 1.82 (1.43-2.31) | <0.001*** |
| IL-6 | 6.49 (4.78-11.27) | 3.92 (2.45-6.07) | <0.001*** |
| IL-10 | 5.20 (3.62-7.86) | 2.99 (2.40-4.37) | <0.001*** |
| IL-17 | 7.69 (3.07-17.61) | 4.80 (2.51-6.01) | 0.005** |
| IFN-γ | 4.20 (2.61-6.91) | 2.60 (2.13-3.56) | 0.002** |
| TNF-α | 3.34 (1.93-5.88) | 2.02 (1.48-2.46) | <0.001*** |
Cytokine levels (pg/ml) in APS group and heathy control group.
ameans that 9 sets of data are lost.
Results are expressed as the median and 25th and 75th percentiles.
Statistics: Mann-Whitney U test.
APS: antiphospholipid syndrome; IL-2: interleukin-2; IL-4: interleukin-4; IL-6: interleukin-6; IL-10: interleukin-10; IL-17: interleukin-17; INF-γ: interferon-γ; TNF-α: tumor necrosis factor-α. *P<0.05, **P<0.01, ***P<0.001.
The original version of this article has been updated.
Summary
Keywords
primary antiphospholipid syndrome (PAPS), secondary antiphospholipid syndrome (SAPS), T helper 17 (Th17) cells, regulatory T (Treg) cells, cytokines
Citation
Frontiers Production Office (2022) Erratum: Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome. Front. Immunol. 13:971769. doi: 10.3389/fimmu.2022.971769
Received
17 June 2022
Accepted
17 June 2022
Published
23 June 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.